ueaeprints.uea.ac.uk€¦ · web viewtrypanosoma. brucei. was investigated. isobolographic...
TRANSCRIPT
Evaluation of trypanocidal activity of combinations of anti-sleeping sickness drugs with cysteine protease inhibitors
Dietmar Steverding*
BioMedical Research Centre, Norwich Medical School, University of East Anglia, Norwich,
United Kingdom
* Corresponding authors at: BioMedical Research Centre, Norwich Medical School,
University of East Anglia, Norwich NR4 7TJ, United Kingdom. Tel.: +44-1603-591291; fax:
+44-1603-591750.
E-mail address: [email protected] (D. Steverding).
1
1
2
3
4
5
6
7
8
9
10
11
1213
A B S T R A C T
Chemotherapy of human African trypanosomiasis (HAT) is unsatisfactory because only a
few drugs, with serious side effects and poor efficacy, are available. As drug combination
regimes often achieve greater therapeutic efficacy than monotherapies, here the trypanocidal
activity of the cysteine protease inhibitor K11777 in combination with current anti-HAT
drugs using bloodstream forms of Trypanosoma brucei was investigated. Isobolographic
analysis was used to determine the interaction between cysteine protease inhibitors (K11777,
CA-074Me and CAA0225) and anti-HAT drugs (suramin, pentamidine, melarsoprol and
eflornithine). Bloodstream forms of T. brucei were incubated in culture medium containing
cysteine protease inhibitors or anti-HAT drugs alone or in combination at a 1:1 fixed-dose
ratio. After 48 h incubation, live cells were counted, the 50% growth inhibition values
determined and combination indices calculated. The general cytotoxicity of drug
combinations was evaluated with human leukemia HL-60 cells. Combinations of K11777
with suramin, pentamidine and melarsoprol showed antagonistic effects while with
eflornithine a synergistic effect was observed. Whereas eflornithine antagonises with CA-
074Me, an inhibitor inactivating the targeted TbCATL only under reducing conditions, it
synergises with CAA0255, an inhibitor structurally related to CA-074Me which inactivates
TbCATL independently of thiols. These findings indicate an essential role of thiols for the
synergistc interaction between K11777 and eflornithine. Encouragingly, the
K11777/eflornithine combination displayed higher trypanocidal than cytotoxic activity. The
results of this study suggest that the combination of the cysteine protease inhibitor K11777
and eflornithine display promising synergistic trypanocidal activity that warrants further
investigation of the drug combination as possible alternative treatment of HAT.
Keywords:
Trypanosoma brucei
Cysteine protease inhibitors
Anti-sleeping sickness drugs
Drug combination
2
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
1. Introduction
Human African trypanosomiasis (HAT) or sleeping sickness is one of the most neglected
tropical diseases. HAT affects mainly poor people living in 250 rural foci scattered over 36
sub-Saharan African countries where it is a major cause for morbidity and mortality (WHO,
2014). The disease is caused by the flagellated protozoan Trypanosoma brucei and
transmitted by the bite of infected tsetse flies. The extracellular parasites live first in the
blood and lymphatic system and later enter the central nervous system causing the typical
symptoms of HAT which are confusion, disturbed sleep pattern, sensory disturbances,
extreme lethargy, poor condition and coma (WHO, 2014). If left untreated, HAT patients will
ultimately die within months or years (WHO, 2014). Sadly, only a few drugs (suramin,
pentamidine, melarsoprol and eflornithine) and one drug combination
(nifurtimox/eflornithine) are currently available for chemotherapy of HAT (Steverding,
2010). All these drugs are outdated and have major drawbacks including poor efficacy,
significant toxicity and the requirement for parental administration (Fairlamb, 2003;
Steverding, 2010). In addition, the compounds are increasingly subject to drug resistance
(Matovu et al., 2001; Delespaux and de Koning, 2007). Hence, effective and better tolerated
chemotherapies are urgently needed for treatment of HAT.
It is well established that drug combination regimes often achieve greater therapeutic
efficacy than monotherapies (e.g. in the treatment of cancer, AIDS and tuberculosis). Drug
combinations may be less toxic than monotherapy regimes and have the additional advantage
of reducing the risk for development of drug resistance. This is because drug combinations
may interact synergistically, i.e. their combined effect may be greater than the sum of their
separate effects (Chou, 2006). However, additive effects are also desirable as they permit
decreased dosage while maintaining efficacy (Chou, 2006). The recently introduced
nifurtimox/eflornithine combination therapy as first line treatment of second stage HAT,
however, failed to show synergistic trypanocidal activity in vitro. Biochemical analysis
revealed that the metabolomic changes associated with the combination are the sum of those
found in each monotherapy with no indication of additional effects (Vincent et al., 2012). In
addition, nifurtimox as a nitro-heterocyclic drug has mutagenic, toxic and carcinogenic side
3
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
effects. Therefore, other drug combinations should be investigated to find combination
therapies with less toxic adverse effects.
Proteases play a key role in the life cycle of T. brucei and in the pathogenicity of HAT
(Steverding, 2013). A chemically validated drug target is the T. brucei cathepsin L-like
protease, TbCATL (aka brucipain, rhodesain or trypanopain-Tb) (Steverding et al., 2012), a
cysteine protease belonging to the C1 family of papain-like enzymes (Caffrey and
Steverding, 2009). TbCATL is found in the lysosome of bloodstream forms of T. brucei
where it is involved in the degradation of endocytosed host proteins (Scory et al., 1999).
Targeting TbCATL with small-molecule inhibitors is trypanocidal both in vitro and in vivo
(Scory et al., 1999; Troeberg et al., 1999; Caffrey et al., 2000). One promising inhibitor that
has emerged over the last 15 years is the peptidomimetic vinyl sulphone K11777 (Fig. 1)
(Caffrey and Steverding, 2008). This inhibitor has been shown to reduce the parasitaemia and
to prolong the survival of T. brucei-infected mice (Caffrey et al., 2000). Considering that
K11777 has been approved by the FDA to enter a phase I safety trial in the United State
(Rodenko and de Koning, 2013), the main aim of this study was to evaluate the trypanocidal
efficacy of K11777 and anti-HAT drug combinations on bloodstream forms of T. brucei in
vitro.
2. Materials and methods
2.1. Drugs
Eflonithine (DL-α-difluoromethylornithine), suramin, pentamidine and CA-074Me ((L-3-
trans-propylcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester) were
purchased from Sigma-Aldrich (Gillingham, UK). Z-FR-AMC (benzyloxycarbonyl-
phenylalanyl-arginyl-7-amido-4-methyl coumarin) was from Enzo Life Sciences Ltd. (Exeter,
UK). Melarsoprol was a gift from Sanofi-Aventis Deutschland GmbH (Frankfurt, Germany).
K11777 ((N-methyl-piperazinyl-phenylalanyl-homophenylalanyl-vinylsulfone-phenyl)) was
4
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
kindly provided by Dr Conor R. Caffrey (University of California San Francisco, USA).
CAA0225 ((2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-
ethyl)-amide] 3-{[2-(4-hydroxy-phenyl)-ethyl]-amide}) was synthesised as previously
described (Steverding et al., 2012).
2.2. Cell Culture
Bloodstream forms of T. brucei clone 427-221a (Hirumi et al., 1980) and human
myelocytic leukemia HL-60 cells (Collins et al., 1977) were grown in Baltz medium (Baltz et
al., 1985) and RPMI 1640 medium (Moore et al., 1967), respectively. Both media were
supplemented with 16.7 % heat-inactivated foetal bovine serum. Trypanosomes and HL-60
cells were cultured at 37°C in a humidified atmosphere containing 5% CO2.
2.3. Isobolographic analysis.
The interaction of drugs was evaluated using the isobolographic method as described
previously (Steverding and Wang, 2009). First, the 50% growth inhibition (GI50) value, i.e.,
the drug concentration necessary to reduce the growth of cells by 50% compared to that of
controls, was determined for each drug. Bloodstream forms of T. brucei were seeded at an
initial density of 104/ml into a 24-well plate in 1 ml medium containing various drug
concentrations. Wells without drugs served as controls. After 48 h of incubation, live
trypanosomes were counted using a haemocytometer. GI50 values were determined by linear
interpolation according to the method described by Huber and Koella (1993). Based on the
GI50 values, trypanosomes were incubated with twofold serially diluted 1:1 ratios of drug
combination. For controls, trypanosomes were cultured with twofold serially diluted
concentrations of each drug alone. After 48 h incubation, live cells were counted and the GI 50
value for each drug in the absence and in the presence of the other co-administered drug was
determined. The combination index (CI) for each drug combination was calculated using the
equation
5
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
GI50(A,com) GI50(B,com)
CI = ————— + —————GI50(A,sin) GI50(B,sin)
where GI50(A,com) and GI50(B,com) are the concentrations of drug A and B used in the combination
to achieve 50% growth inhibition and GI50(A,sin) and GI50(B,sin) are the concentrations for the
single drugs to achieve the same effect. A CI value of <1, =1, and >1 indicates synergism,
additive effect, and antagonism, respectively.6
2.4. TbCATL activity assay
The effect of the cysteine protease inhibitors K11777, CA-074Me and CAA0225 on the
catalytic activity of recombinant TbCATL was determined by pre-incubating the enzyme (6.1
μg/ml) with 100 μM of the compounds in 100 mM citrate, pH 5, 10% DMSO, in the presence
or absence of 1.5 mM DTT for 2 h. Controls were treated with 10% DMSO alone in the
presence or absence of 1.5 mM DTT for the same period of time. Then, 50 μl of the enzyme
solution was added to 1950 μl measuring buffer (100 mM citrate, pH 5, 2 mM DTT)
containing 10 μM Z-FR-AMC. The final enzyme concentration in the assay was 0.305 μg/ml.
After 10 min incubation at room temperature, the reaction was stopped by adding iodoacetic
acid to a final concentration of 5 mM. Release of 7-amino-4-methylcoumarin (AMC) was
measured at excitation and emission wavelengths of 360 and 460 nm in a BIORAD
VersaFlour fluorometer. Data were calculated as specific activity (pmol AMC
released/min/μg protein) using a standard curve constructed with AMC.
2.5. Cytotoxic evaluation of drug combinations
The general toxicity of drug combinations that act synergistically on trypanosomes was
assayed with HL-60 cells. Drugs were tested alone or together at 1, 10 and 100 the
concentration of the drugs in the combination that inhibited the growth of trypanosomes by
6
130131132133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
50%. HL-60 cells were seeded at an initial density of 105/ml into a 24-well plate in 1 ml
medium in the presence of the drugs to be tested. After 48 h incubation, live cells were
counted using a haemocytometer in the presence of the vital dye Trypan Blue.
3. Results and discussion
Combinations of K11777 with suramin, pentamidine or melarsoprol showed antagonistic
effects with CIs of 1.67±0.43, 1.46±0.10 and 1.46±0.08, respectively (Fig. 2A-C). Whereas
the GI50 of K11777 dropped from around 3.5 μM to about 2.0 μM, the GI50 of all three anti-
HAT drugs remained almost unchanged (suramin: from 0.10±0.02 to 0.10±0.03 μM;
pentamidine: from 10.3±1.9 to 8.3±0.4 nM; melarsoprol: from 9.6±0.5 to 8.7±0.2 nM). These
results indicate that lysosomal TbCATL activity, the enzyme activity targeted by K11777,
may play a role in the trypanocidal action of the three anti-HAT drugs. At least for suramin
this suggestion seems to be true as TbCATL knock down bloodstream form trypanosomes
display a fourfold lower sensitivity for the drug (Alsford et al., 2012).
In contrast to suramin, pentamidine and melarsoprol, eflornithine in combination with
K11777 showed a synergistic effect with a CI of 0.67±0.22 (Fig. 2D). The GI50 of K11777
dropped from 3.6±0.5 to 0.9±0.2 μM and the GI50 of eflornithine from 41.2±4.0 to 17.1±4.5
μM. As eflornithine inhibits the polymanine biosynthesis leading to a decrease in the
concentration of trypanothione (the glutathione analogue in trypanosomes) (Fairlamb et al.,
1987), and as the activity of TbCATL is dependent on thiols (Troeberg et al., 1996), it is
reasonable to suggest that the synergistic effect of the K11777/eflornithine combination is
associated with a reduced thiol concentration in the lysosome. In this context it should be
mentioned that the intralysosomal milieu has been shown to be a reducing environment
(Pisoni et al., 1990). To prove the suggestion, another cysteine protease inhibitor, CA-074Me
(Fig. 1), which in contrast to K11777 inhibits TbCATL only under reducing conditions
(Table 1) (Steverding et al., 2012), was tested in combination with eflornithine. The CA-
074Me/eflornithine combination showed an antagonistic effect with a CI of 1.33±0.09 (Fig.
3A). Accordingly, the GI50 of both compounds decreased only a little (CA-074Me: from
7
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
8.6±0.6 to 5.1±0.7 μM; eflornithine: from 39.3±3.2 to 28.0±7.9 μM). To rule out the
possibility that the observed difference in the interaction between the two cysteine protease
inhibitor and eflornithine is due to their differences in structure and pharmacophore (K11777
is a vinyl sulphone whereas CA-074 is an oxirane), a third cysteine protease inhibitor
structurally related to CA-074Me, CAA0225 (Fig. 1), which inhibits TbCATL independently
of thiols (Table 1) (Steverding et al., 2012), was also tested. In contrast to CA-074Me,
CAA0225 showed a synergistic effect in combination with eflornithine with a CI of
0.89±0.17 (Fig. 3B). The drop in GI50 values of CAA0225 (from 1.8±0.6 to 0.6±0.1 μM) and
eflornithine (from 40.7±3.8 to 21.6±2.6 μM) was of similar extent compared to that of
K11777 and eflornithine (see above). These results confirm the suggestion that the
underlying mechanism for synergy of the K11777/eflornithine combination is indeed
facilitated by the reduction in thiol levels. This suggested mechanism is further corroborated
by the observation that eflornithine antagonises with suramin whose trypanocidal action
relies on the activity of the thiol-dependent TbCATL (Alsford et al., 2012).
The general cytotoxicity of the K11777/eflornithine combination which acted
synergistically on trypanosomes was assayed with human myeloid leukaemia HL-60 cells.
The concentration that inhibited the growth of bloodstream forms of T. brucei by 50% (0.9
μM K11777/17.1 μM eflornithine; see Fig. 2D) had no effect on the proliferation of HL-60
cells (Fig. 4). Even a 10-fold higher concentration (9 μM K11777/171 μM eflornithine)
slowed down the growth of HL-60 cells by only 25% (Fig. 4). However, a 100-fold higher
concentration (90 μM K11777/1710 μM eflonithine) was toxic to the human cells whereby
the cytotoxic effect of the combination was almost entirely due to the action of the cysteine
protease inhibitor K11777 (Fig. 4). It should be noted that HL-60 cells compared to non-
malignant cells are generally more sensitive to cytotoxic drugs as, for example, has been
recently shown for the ionophore salinomycin (Steverding and Sexton, 2013). Thus,
compared to normal cells, the cytotoxicity of the K11777/eflornithine combination
determined with HL-60 cells is likely to be overestimated.
This study has shown that the cysteine protease inhibitor K11777 acts synergistically with
the anti-HAT drug eflornithine to inhibit the growth of bloodstream forms of T. brucei and
8
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
that the synergistic interaction between the two drugs was due to a reduction in thiols levels.
In addition, the K11777/eflornithine combination was found to be less toxic to human HL-60
cells than to trypanosomes. These findings suggest that the combination of K11777 and
eflornithine could be developed into an alternative treatment of HAT. However, as this was
an in vitro study, further investigations are required in order to establish the in vivo efficacy
of the K11777/eflornithine combination. In this respect, it is worth mentioning that K11777 is
currently undergoing clinical trials as a potential new drug for the treatment of Chagas
disease caused by Trypanosoma cruzi. As in T. brucei, K11777 also targets a cathepsin L-like
protease in T. cruzi, TcCATL, which is closely related to TbCATL (Caffrey and Steverding,
2009). In addition, both enzymes are found in the lysosome of both parasites (although
TcCATL has been additionally localized to the prelysosomal reservasome, the flagellar
pocket and the plasma membrane) and contribute to nutrient processing (Sajid et al., 2011).
Moreover, both TbCATL and TcCATL prefer basic and bulky, hydrophobic residues in the
S1 subsite and in the S2 subsite, respectively (Dunny et al., 2013). As both enzymes share
common features, it is reasonable to assume that the soon available pharmacokinetic and
pharmacodynamic data for K11777 from the clinical trials will help with the design of in vivo
studies to determine the efficacy of the compound in combination with eflornithine to cure
animals experimentally infected with T. brucei.
Acknowledgements
I thank Dr Darren Sexton for critical reading of the manuscript.
9
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240241
References
Alsford, S., Eckert, S., Baker, N., Glover, L., Sanchez-Flores, A., Leung, K.F., Turner, D.J.,
Field, M.C., Berriman, M., Horn, D., 2012. High-throughput decoding of
antitrypanosomal drug efficacy and resistance. Nature 482, 232-236.
Baltz, T., Baltz, D., Giroud, C., Crockett, J., 1985. Cultivation in a semi-defined medium of
animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense
and T. gambiense. EMBO J. 4, 1273-1277.
Caffrey, C.R., Steverding, D., 2008. Recent initiatives and strategies to developing new drugs
for tropical parasitic diseases. Expert Opin. Drug Discov. 3, 173-186.
Caffrey, C.R., Steverding, D., 2009. Kinetoplastid papain-like cysteine peptidases. Mol.
Biochem. Parasitol. 167, 12-19.
Caffrey, C.R., Scory, S., Steverding, D., 2000. Cysteine proteinases of trypanosome parasites:
novel targets for chemotherapy. Curr. Drug Targets 1, 155-162.
Chou, T.C., 2006. Theoretical basis, experimental design, and computerized simulation of
synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681.
Collins, S.J., Gallo, R.C., Gallagher, R.E., 1977. Continuous growth and differentiation of
human myeloid leukaemic cells in suspension cultures. Nature 270, 347-349.
Delespaux, V., de Koning, H.P., 2007. Drugs and drug resistance in African trypanosomiasis.
Drug Resist. Updat. 10, 30-50.
Dunny, E., Doherty, W., Evans, P., Malthouse, J.P.G., Nolan, D., Knox, A.J.S., 2013. Vinyl
sulfone-based peptidomimetics as anti-trypanosomal agents: design, synthesis, biological
and computational evaluation. J. Med. Chem. 56, 6638-6650.
Fairlamb, A.H., 2003. Chemotherapy of human African trypanosomiasis: current and future
prospects. Trends Parasitol. 19, 488-494.
Fairlamb, A.H., Henderson, G.B., Bacchi, C.J., Cerami, A., 1987. In vivo effects of
difluoromethylormithine on trypanothione and polyamine levels in bloodstream forms of
Trypanosoma brucei. Mol. Biochem. Parasitol. 24, 185-191.
10
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
Hirumi, H., Hirumi, K., Doyle, J.J., Cross, G.A., 1980. In vitro cloning of animal-infective
bloodstream forms of Trypanosoma brucei. Parasitology 80, 371-382.
Huber, W., Koella, J.C., 1993. A comparison of three methods of estimating EC50 in studies
of drug resistance of malaria parasites. Acta Trop. 55, 257-261.
Matovu, E., Seebeck, T., Enyaru, J.C., Kaminsky, R., 2001. Drug resistance in Trypanosoma
brucei ssp., the causative agents of sleeping sickness in man and nagana in cattle.
Microbes Infect. 3, 763-770.
Moore, G.E., Gerner, R.E., Franklin, H.A., 1967. Culture of normal human leukocytes. J.
Am. Med. Assoc. 199, 519-524.
Pisoni, R.L., Acker, T.L., Lisowski, K.M., Lemons, R.M., Thoene, J.G., 1990. A cysteine-
specific lysosomal transport system provides a major route for the delivery of thiol to
human fibroblast lysosomes: possible role in supporting proteolysis. J. Cell Biol. 110,
327-335.
Rodenko, B., de Koning, H.P., 2013. Rational selection of anti-microbial drug targets: unique
or conserved? In: Jäger, T., Koch, O., Flohé, L. (Eds), Trypanosomatid Diseases:
Molecular Routes to Drug Discovery. Wiley-VCH, Weinheim, pp. 281-296.
Sajid, M., Robertson, S.A., Brinen, L.S., McKerrow, J.H., 2011. Cruzain: the path from target
validation to the clinic. Adv. Exp. Med. Biol. 712, 100-115.
Scory, S., Caffrey, C.R., Stierhof, Y.D., Ruppel, A., Steverding, D., 1999. Trypanosoma
brucei: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase
inhibitor Z-Phe-Ala-CHN2. Exp. Parasitol. 91, 327-333.
Steverding, D., 2010. The development of drugs for treatment of sleeping sickness: a
historical review. Parasit. Vectors 3, 15.
Steverding, D., 2013. Proteases of Trypanosoma brucei. In: Jäger, T., Koch, O., Flohé, L.
(Eds), Trypanosomatid Diseases: Molecular Routes to Drug Discovery. Wiley-VCH,
Weinheim, pp. 365-382.
Steverding, D., Wang, X., 2009. Evaluation of anti-sleeping sickness drugs and
topoisomerase inhibitors in combination on Trypanosoma brucei. J. Antimicrob.
Chemother. 63, 1393-1395.
11
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
Steverding, D., Sexton, D.W., 2013. Trypanocidal activity of salinomycin is due to sodium
influx followed by cell swelling. Parasit. Vectors 6, 78.
Steverding, D., Sexton, D.W., Wang, X., Gehrke, S.S., Wagner, G.K., Caffrey, C.R., 2012.
Trypanosoma brucei: chemical evidence that cathepsin L is essential for survival and a
relevant drug target. Int. J. Parasitol. 42, 481-488.
Troeberg, L., Pike, R.N., Morty, R.E., Berry, R.K., Coetzer, T.H., Lonsdale-Eccles, J.D.,
1996. Proteases from Trypanosoma brucei brucei. Purification, characterisation and
interactions with host regulatory molecules. Eur. J. Biochem. 238, 728-736.
Troeberg, L., Morty, R.E., Pike, R.N., Lonsdale-Eccles, J.D., Palmer, J.T., McKerrow, J.H.,
Coetzer, T.H., 1999. Cysteine proteinase inhibitors kill cultured bloodstream forms of
Trypanosoma brucei brucei. Exp. Parasitol. 91, 349-355.
WHO, 2014. Trypanosomiasis, human African (sleeping sickness). World Health Org. Fact
Sheet 259. http://www.who.int/mediacentre/factsheets/fs259/en/. Accessed 18 August
2014.
Vincent, I.M., Creek, D.J., Burgess, K., Woods, D.J., Burchmore, R.J., Barrett, M.P., 2012.
Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine
against Trypanosoma brucei. PLoS Neg. Trop. Dis. 6, e1618.
12
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315316
Tables
Table 1
Effect of dithiothreitol (DTT) on the inhibition of TbCATL by cysteine protease inhibitors
Inhibitor
Activity as pmol/min/μg protein (%)a
‒ DTT + DTT
DMSO 515±74 (100%) 802±112 (100%)
K11777 24±3 (4.7%) 1±1 (0.1%)
CA-074Me 522±67 (101.1%) 7±2 (0.9%)
CAA0225 31±2 (6.0%) 1±1 (0.1%)
Recombinant TbCATL was pre-treated with 100 μM of inhibitor or equivalent volume of
DMSO in the absence or presence of 1.5 mM DTT and 2 h later assayed for hydrolysis of Z-
FR-AMC. Data are means ± SD of three independent experiments.
a Percent activity relative to DMSO controls.
13
317
318
319
320
321
322
323
324325
Figure legends
Fig. 1. Chemical structures of K11777, CA-074Me and CAA0225.
Fig. 2. Isobolographic plot for the interaction between K11777 and suramin (A), pentamidine
(B), melarsorpol (C), and eflornithine (D). Bloodstream forms of T. brucei were incubated
with twofold serial dilutions of drug combinations (1:1) or drugs alone. After 48 h of
incubation, live cells were counted and GI50 values determined. The dotted line that connects
the GI50 points for the single drug treatments (filled squares) is the theoretical additive line.
The GI50 of the combinations is indicated by open circles. Each point represents the mean ±
SD of three independent experiments.
Fig. 3. Isobolographic plot for the interaction between eflornithine and CA-074Me (A), and
CAA0225 (B). For experimental details see Fig. 2.
Fig. 4. Effect of eflornithine and K11777 on the growth of HL-60 cells. Cells were incubated
with eflornithine alone (dark grey columns), eflornithine/K11777 combined (medium grey
columns) or K11777 alone (light grey columns) at 1, 10 or 100 of the drug combination
that inhibited the growth of trypanosomes by 50% (17.1 μM and 0.9 μM, respectively). Mean
values ± SD of three independent experiments are shown.
14
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345346
Figure 1
O
NH
NH
SO O
O
N
NCH 3
K11777
OCH 3
O
N
O
NH
O
ONH
O
CA-074Me
NH O
O
NH
OHO
O
NH
CAA0225
15
347
348
349
350
351
352
353
354
355
356
357
358
359360
Figure 2
A
0
1
2
3
4
0 0.03 0.06 0.09 0.12
K11
777
(μM
)
Suramin (μM)
B
0
1
2
3
4
0 2 4 6 8 10 12
K11
777
(μM
)
Pentamidine (nM)
16
361362363
364365
366367
Figure 2 (cont.)
C
0
1
2
3
4
0 2 4 6 8 10
K11
777
(μM
)
Melarsoprol (nM)
D
0
1
2
3
4
0 10 20 30 40
K11
777
(μM
)
Eflornithine (μM)
17
368369370
371372
373374
Figure 3
A
0
2
4
6
8
0 10 20 30 40
CA-
074M
e (μ
M)
Eflornithine (μM)
B
0
0.6
1.2
1.8
2.4
0 10 20 30 40
CAA
0225
(μM
)
Eflornithine (μM)
18
375376377
378379
380381
Figure 4
0
20
40
60
80
100
120
1X 10X 100X
Cel
l Gro
wth
(% o
f Con
trol
)
Concentration of DFMO/K11777 (17.1 μM/0.9 μM)
DFMO DFMO/K11777 K11777
19
382
383
384